AbbVie’s rheumatoid arthritis drug upadacitinib is at the top of a new list of drugs due to launch this year that are expected to make blockbuster sales by 2023.
Takeda’s experimental epilepsy drug soticlestat has failed not one but two phase 3 trials – in Dravet syndrome and Lennox-Gastaut syndrome – throwing the future of the programme in doubt.